Clincosm LogoSign in Get a demo

High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes

Sponsor
Korea University (Other)
Overall Status
Completed
CT.gov ID
NCT01099865
Collaborator
(none)
56
Enrollment
1
Location
4
Duration (Months)
14.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The UKPDS risk score is recommended to assess global risk for future coronary heart disease (CHD) events in primary prevention. Recently, high-sensitivity C-reactive protein (hsCRP) has emerged as a strong independent risk factor for CHD. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising imaging technique for the evaluation of vascular inflammation that reflects vulnerable atherosclerotic plaque.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    56 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    High-sensitivity C-reactive Protein and UKPDS Risk Score in Type 2 Diabetes: Nalysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
    Study Start Date :
    Dec 1, 2009
    Actual Primary Completion Date :
    Apr 1, 2010
    Actual Study Completion Date :
    Apr 1, 2010

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      16 Years to 80 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Type 2 diabetes
      Exclusion Criteria:

      • Myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization

      • Resting blood pressure ≥160/100 mmHg

      • Malignancy, or severe renal or hepatic disease

      • Participants were free of any lipid-lowering therapies and postmenopausal hormone replacement therapy at least the 6 month period prior to enrollment

      • History of inflammatory condition or those taking medications that might affect inflammatory status within 6 months

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Korea University Guro Hospital Dept. of Endocrinology Seoul Korea, Republic of

      Sponsors and Collaborators

      • Korea University

      Investigators

      None specified.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT01099865
      Other Study ID Numbers:
      • PET(DM)
      First Posted:
      Apr 8, 2010
      Last Update Posted:
      Apr 8, 2010
      Last Verified:
      Apr 1, 2010
      Additional relevant MeSH terms:
      Atherosclerosis
      Diabetes Mellitus
      Diabetes Mellitus, Type 2

      Study Results

      No Results Posted as of Apr 8, 2010